more_reports

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2

  ()
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

  ()
Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances

  ()
REGENXBIO's RGX-121 gene therapy faces an FDA clinical hold after spinal MRI findings, while the Duchenne muscular dystrophy program remains on track for its Q3 2026 BLA submission, along with wet AMD pivotal data expected in Q4.
Tags: Biotechnology / Pharmaceuticals

REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy

  ()
REGENXBIO Inc. (RGNX:NASDAQ) faces an FDA clinical hold on RGX-121 after spinal MRI findings in five patients, while its Duchenne and wet AMD programs remain on track.
Tags: Biotechnology / Pharmaceuticals

Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish

  ()
Coya Therapeutics moves COYA 302 through Phase 2 ALSTARS for ALS with enrollment completion expected in 2026 and topline data in Q1 2027. Learn key catalysts, pipeline details, and analyst targets.
Tags: Biotechnology / Pharmaceuticals

Is This Biopharmaceutical Co. Developing ALS Drug a Buy?

  ()
Read to find out what analysts think of Houston-based Coya Therapeutics Inc. (COYA:NASDAQ), which is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative, autoimmune, and metabolic diseases.
Tags: Biotechnology / Pharmaceuticals

Ultragenyx Delivers First Gene Therapy FDA Approval for GSDIa

  ()
Ultragenyx earns FDA approval for GENGLYCOS, its first gene therapy for GSDIa in patients aged 8 and older. Phase 3 data showed reduced cornstarch needs, with analyst price targets rising and a September UX111 decision ahead.
Tags: Biotechnology / Pharmaceuticals

FDA Approves GENGLYCOS, Ultragenyx's First Gene Therapy

  ()
The FDA granted accelerated approval to GENGLYCOS, Ultragenyx Pharmaceutical Inc.'s first gene therapy, for adults and pediatric patients eight years and older with GSDIa, based on Phase 3 data showing a reduction in daily cornstarch intake.
Tags: Biotechnology / Pharmaceuticals

Rocket Doctor AI Secures California Network Deal Reaching 60M Consumers

  ()
Rocket Doctor AI enters a major provider network agreement in California covering 60 million consumers across multiple lines including workers compensation and Medicare. Learn the key details and next steps for investors.
Tags: Life Sciences Tools & DiagnosticsArtificial Intelligence

Rocket Doctor AI Signs Strategic Network Agreement to Expand California Reimbursement Access

  ()
New multi-channel partnership opens contracted entry points into workers' compensation, auto medical, and Medicare networks, further extending Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) U.S. partnering strategy.
Tags: Life Sciences Tools & DiagnosticsArtificial Intelligence

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline

  ()
Sarepta Therapeutics reports Q2 2026 results with $328.7M product revenue and new CEO Michael Severino leading pipeline progress in rare diseases. Read the latest on SRPT financials and catalysts.
Tags: Biotechnology / Pharmaceuticals

DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances

  ()
Satellos Bioscience reports positive six-month DMD trial data and FDA Fast Track status. Learn about its cash position, upcoming pediatric results, and analyst price targets.
Tags: Biotechnology / Pharmaceuticals

Cleantech Developer Advances Five Platforms With 26% Revenue Growth

  ()
BioLargo reports 26% revenue growth excluding exited line, 54% gross margins and subsidiary-led funding model across medical, water and energy businesses.
Tags: CleantechTechnologyHealthcare ServicesSpecial Situations

Cleantech Firm Raises 86% of Capital Without Selling Stock

  ()
Cleantech innovator BioLargo Inc. (BLGO:OTCQX) files its financial results for the three and six months ended June 30. Find out how the company funded its five businesses while raising 86% of its capital without selling BioLargo stock.
Tags: CleantechTechnologyHealthcare ServicesSpecial Situations

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Sarepta Posts US$328.7M Results

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) reported US$328.7 million in Q2 2026 product revenue, with data readouts expected in DMD and FSHD this year.
Tags: Biotechnology / Pharmaceuticals

Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has reported six-month TRAILHEAD data showing reduced muscle fat fraction and increased effort among the four adult DMD participants included in the interim analysis.
Tags: Biotechnology / Pharmaceuticals

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

  ()
Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

  ()
Doximity Inc. (DOCS:NYSE) reported 7% revenue growth as workflow active prescribers increased more than 30% year over year and AI Search queries climbed more than 25% quarter over quarter.
Tags: Life Sciences Tools & DiagnosticsMedical Devices

AI Cancer Drug Developer Advances Pipeline as Funding Expands

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing in vivo testing and AI-driven lead optimization across its cancer drug pipeline as it expands relationships with AI companies and pursues additional non-dilutive funding.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics